Quick Summary
- IV NAD+ pushes hit 100% bioavailability but generate brutal flushing, chest tightness, and abdominal cramping as the bolus floods the system.
- Subcutaneous depot NAD+ creates a slow-release reservoir under the skin, achieving 70-85% of IV’s tissue NAD+ elevation with a fraction of the discomfort.
- Oral NMN and NR work for daily maintenance but cannot match the magnitude of NAD+ elevation that depot or IV achieves.
- Typical depot protocol: 100-300mg subcutaneous, every 5-7 days, in the lower abdomen rotating injection sites.
- The Natural Plus angle: depot first, then add oral NMN for daily maintenance. Use the depot for the elevation, use the oral for the floor.
The NAD+ industry has converged on two extremes. On one end, $1,500-per-bag IV NAD+ at longevity clinics that takes 4 hours of misery to push. On the other end, $80 bottles of NMN powder that may or may not even be raising your NAD+ depending on which study you trust. Neither is the right answer for most Enhanced Men.
The right answer is the protocol nobody is selling because it cannot be branded: subcutaneous depot NAD+, dosed at home, supplemented with oral NMN for daily maintenance. It is the protocol that the longevity clinic doctors use on themselves.
The Biochemistry: What NAD+ Actually Does and Why You Need More
NAD+ is the cofactor every redox reaction in your body depends on. It carries electrons in glycolysis, fatty acid oxidation, the citric acid cycle, and oxidative phosphorylation. It is the substrate for sirtuins (SIRT1-7), which gate gene expression around metabolism, inflammation, and DNA repair. It is the substrate for PARP enzymes, which repair DNA damage. It is the substrate for CD38, which is why CD38 inhibitors are a separate longevity strategy.
NAD+ levels decline roughly 1-2% per year after age 40. By 60, you are at half of your 20-year-old NAD+ levels. Sirtuins lose function. DNA repair degrades. Mitochondrial efficiency drops. This is not abstract longevity research — this is the bottleneck driving most of the metabolic dysfunction people experience as aging.
The question is not whether to raise NAD+. The question is how, with what magnitude, and how often.
Why Oral NMN Plateaus
NMN crosses the gut and enters circulation. It crosses cell membranes via the Slc12a8 transporter. It gets converted to NAD+. The math works. The problem is the magnitude.
Oral NMN at 500-1000mg per day raises plasma NAD+ by roughly 30-60% in most users. That is meaningful. It is not transformative. To get the magnitude of elevation that produces sirtuin-level effects on metabolism and DNA repair, you need to spike NAD+ above what oral dosing can achieve.
This is the Tony Huge Laws of Biochemistry Physics — specifically Law 3, the Chain Bottleneck. Oral NMN floods the precursor, but the conversion enzymes (NMNAT1-3) are rate-limited. Past a certain plasma NMN level, you are wasting NMN. The bottleneck is downstream. Pushing more precursor does not break the bottleneck. You need a different delivery route that puts the active molecule closer to the destination.
Why IV NAD+ Is Brutal
IV NAD+ bypasses every absorption and conversion step. The molecule lands directly in plasma at high concentration. That is the upside.
The downside is that NAD+ at high plasma concentration causes immediate vasoactive effects: flushing, chest pressure, abdominal cramping, headache, and an unpleasant feeling that has been described by users as “the worst niacin flush of your life that lasts four hours.” This is why IV protocols are slow-pushed over 2-4 hours. The slower the push, the milder the symptoms, the longer you sit in the chair.
For most Enhanced Men, this is a 4-hour misery commitment every 2-4 weeks. It works. It is not sustainable.
The Subcutaneous Depot Approach
Subcutaneous NAD+ creates a localized depot under the skin. The molecule diffuses slowly into systemic circulation over 8-24 hours, depending on dose. That slow release achieves the magnitude of elevation that oral NMN cannot match, without the bolus-spike side effects of IV.
Tissue NAD+ measurements in users running this protocol show roughly 70-85% of the elevation achieved by an equivalent IV dose, sustained over a longer window. The pharmacokinetics are arguably better than IV for sirtuin activation, because sirtuins respond to integrated NAD+ exposure, not peak concentration.
This is Law 4 of the Tony Huge Laws of Biochemistry Physics — Self-Regulating Systems — in action. The body’s NAD+ salvage pathway, NAD+ degradation enzymes, and CD38 activity all respond to plasma NAD+ concentration. A sustained moderate elevation produces less counter-regulatory degradation than a high spike. Depot dosing works with homeostasis, not against it.
Natural Plus Protocol
- Dose: Start at 50mg subcutaneous to test tolerance. Titrate up to 100-300mg per dose.
- Frequency: Every 5-7 days. Some users go every 3-4 days during a 4-week loading phase, then transition to weekly.
- Injection site: Lower abdomen, rotating sides. Avoid the same site within 5 days.
- Reconstitution: Bacteriostatic water. Refrigerate. Use within 21 days.
- Daily maintenance: 500-1000mg oral NMN or NR continued throughout. The depot provides peaks, the oral provides the floor.
- Co-factors: TMG (trimethylglycine) 500-1000mg daily to support methyl donor pool, which is consumed by NAD+ metabolism. Pull homocysteine at baseline and 8 weeks to monitor.
- Bloodwork: Comprehensive metabolic panel and CRP at baseline and 12 weeks. Some users now have access to direct NAD+ measurements via dried blood spot panels.
Stacking Recommendations
Per Law 5 of the Tony Huge Laws of Biochemistry Physics, NAD+ depot stacks well with compounds hitting independent pathways:
- Apigenin — CD38 inhibitor. CD38 is the major NAD+-degrading enzyme, and CD38 expression rises with age. Apigenin slows the leak, NAD+ depot fills the bucket. See apigenin and CD38 inhibition.
- Spermidine — autophagy activator that works synergistically with sirtuin signaling. See spermidine deep dive.
- Methylene blue — alternative electron carrier that supports mitochondrial efficiency under NAD+ elevation. See methylene blue protocol.
- Urolithin A — mitophagy activator. NAD+ supports new mitochondrial function, urolithin A clears damaged mitochondria. Complementary. See urolithin A.
Target Audience
NAD+ depot makes sense for: Enhanced Men over 35 who have plateaued on oral NMN, people running aggressive longevity stacks who need magnitude of NAD+ elevation, and anyone recovering from a major metabolic insult (post-illness, post-injury, post-aggressive cycle). It does not make sense for: people under 30 with no measurable NAD+ deficit, anyone who has not yet dialed sleep, training, and basic supplementation.
Timeline / Results
| Timeframe | What to Expect |
|---|---|
| Week 1 | Mild injection site warmth, subtle energy lift 12-24 hours post-dose. |
| Week 4 | Noticeable improvement in training recovery and sleep quality. |
| Week 8 | Visible skin and hair improvements, sustained energy floor. |
| Week 12 | CRP typically down, training capacity meaningfully higher. |
Interesting Perspectives
The conversation nobody in the NAD+ industry wants to have: CD38 expression is what is actually driving the age-related NAD+ decline. NAD+ supplementation without addressing CD38 is filling a leaky bucket. The leverage move is to combine NAD+ elevation (depot or oral) with CD38 inhibition (apigenin, quercetin, or experimental CD38 inhibitors in the pipeline). The clinics charging $1,500 per IV without an apigenin protocol attached are leaving the actual mechanism on the table.
Contrarian take: the entire NMN-vs-NR debate has been irrelevant for two years. Both work orally. Both plateau at similar magnitudes. The interesting question is route of administration, not which precursor. The industry sold a debate about molecule choice while ignoring that the binding constraint was bioavailability and downstream NAD+ leak.
Cross-domain connection: NAD+ depot dosing parallels how thyroid medicine evolved from once-daily T4 to T4 + T3 + slow-release protocols. The recognition that magnitude AND temporal pattern of hormone exposure both matter. NAD+ is heading the same direction. Continuous moderate elevation outperforms intermittent spikes for sirtuin activation, but the daily oral floor needs the periodic depot peak to keep the integrated exposure high enough.
FAQ
Is subcutaneous NAD+ better than IV? For most users, yes. You get 70-85% of the tissue NAD+ elevation with a small fraction of the side-effect burden and zero chair time.
What dose of subcutaneous NAD+ should I start with? 50mg to test tolerance, then titrate to 100-300mg per dose, every 5-7 days.
Can I just take oral NMN instead? Oral NMN provides a daily floor but plateaus around 30-60% NAD+ elevation. The depot achieves elevations oral dosing cannot reach.
Do I need TMG with NAD+ depot? Yes. Methyl groups are consumed by NAD+ metabolism. TMG 500-1000mg daily prevents homocysteine drift.
Who should not use NAD+ depot? Anyone with active cancer (NAD+ supports DNA repair in malignant cells), anyone with severe cardiovascular instability, and anyone who has not pulled a baseline metabolic panel.
Cross-Reference
For the foundational longevity stack see the Enhanced Athlete Protocol hub. For oral NAD+ precursor comparison see NAD+ injection vs oral NMN. For supplements that pair with NAD+ work, Protocol: Supplements. For bloodwork monitoring, Protocol: Bloodwork.